John C. Cheville, M.D.

Closed for Enrollment

• Comprehensive Profiling of Blood Immune Biomarkers in Bladder Cancer Rochester, Minn.

  The purpose of this study is to characterize the immune markers of granulocytes, lymphocytes and monocytes in peripheral blood of newly diagnosed bladder cancer patients.

• Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine Rochester, Minn.

  Primary Aims

  1. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors.
  2. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors.

   

• ROR1751: Genetic Biomarker Discovery for Metastatic Prostate Cancer Rochester, Minn.

  Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.